Moxifcin Eye Drops Special Precautions

For ocular use only. Not for injection. This product should not be injected subconjunctivally or introduced directly into the anterior chamber of the eye.
In patients receiving systemically administered quinolones, serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported, some following the first dose. Some reactions were accompanied by cardiovascular collapse, loss of consciousness, angioedema (including laryngeal, pharyngeal or facial oedema), airway obstruction, dyspnoea, urticaria, and itching.
If an allergic reaction to this product occurs, discontinue use of the product. Serious acute hypersensitivity reactions may require immediate emergency treatment. Oxygen and airway management should be administered where clinically indicated.
As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy.
Whenever clinical judgment dictates, the patient should be examined with the aid of magnification, such as slit-lamp biomicroscopy, and, where appropriate, fluorescein staining.
Tendon inflammation and rupture may occur with systemic fluoroquinolone therapy including moxifloxacin, particularly in elderly patients and in those treated concurrently with corticosteroids. Therefore, treatment with this product should be discontinued at the first sign of tendon inflammation.
Patients should be advised not to wear contact lenses if they have signs and symptoms of bacterial conjunctivitis.
Effects on ability to drive and use machines: Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines.
If blurred vision occurs at application, the patient must wait until the vision clears before driving or using machinery.
Use in Children: The safety and effectiveness of Moxifloxacin in infants below 1 year of age have not been established.
There is no evidence that the ophthalmic administration of Moxifloxacin has any effect on weight bearing joints, even though oral administration of some quinolones has been shown to cause arthropathy in immature animals.
Use in the Elderly: No overall differences in safety and effectiveness have been observed between elderly and younger patients.